NTQ1062 plus fulvestrant for advanced HR+/HER2- breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug, NTQ1062, combined with fulvestrant in people with a type of breast cancer called HR-positive, HER2-negative that has spread or come back. The study aims to see if this combination helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HR-positive and HER2-negative and has spread or come back after prior treatment.
- You have had at least one prior hormone therapy (like an aromatase inhibitor or tamoxifen).
- You have a tumor that can be measured on a scan or a bone lesion that can be seen on imaging.
- You are in good enough health to be up and around (ECOG score 0 or 1).
- You must not have used fulvestrant or certain other drugs before (like PI3K/mTOR/Akt inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.